Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2025)
Telix Pharmaceuticals (TLX) posted Non-Current Debt of $391.9 million for Q4 2025, up 8.6% on a QoQ basis from $360.9 million in Q4 2024, and up 8.6% year-over-year from $360.9 million in Q4 2024.
Telix Pharmaceuticals (TLX) has 3 years of Non-Current Debt data on file, last reported at $391.9 million in Q4 2025.
- In Q4 2025, Non-Current Debt rose 8.6% year-over-year to $391.9 million; the TTM figure through Dec 2025 stood at $391.9 million (up 8.6% YoY), while the FY2025 annual figure was $391.9 million, up 14.66% from the prior year.
- Non-Current Debt grew to $391.9 million in Q4 2025, from $360.9 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $391.9 million in Q4 2025 and bottomed at $5.3 million in Q4 2023.
- A 3-year average of $252.7 million and a median of $360.9 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt soared 6652.77% — and 2025, when it increased 8.6%.
- Year by year, Non-Current Debt stood at $5.3 million in 2023, then jumped by 6652.77% to $360.9 million in 2024, then advanced by 8.6% to $391.9 million in 2025.
- The last three Non-Current Debt figures came in at $391.9 million (Q4 2025), $360.9 million (Q4 2024), and $5.3 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Telix Pharmaceuticals | 4.52 Bn | 4.38 Bn | - | 391.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 391.91 Mn |
| Dec 31, 2025 | 391.91 Mn |
| Dec 31, 2024 | 360.87 Mn |
| Dec 31, 2024 | 360.87 Mn |
| Dec 31, 2023 | 5.34 Mn |
| Dec 31, 2023 | 5.34 Mn |